Free Newsletter
Stem cell research tops Obama agenda
Although the economy is clearly the priority for the new President-elect, Barack Obama's still growing team has indicated that he has already begun reviewing President George W. Bush's executive orders to decide which ones should stay, which will be repealed and which need to be amended. And stem cell research is among the top issues Obama is likely to tackle once in office, Chief of Staff Rahm Emanuel, tells the Wall Street Journal.
"Bucket one would have children's health care, Schip," said Emanuel. "It has bipartisan agreement in the House and Senate. It's something President-elect Obama expects to see. Second would be [ending current restrictions on federally funded] stem-cell research. And third would be an economic recovery package focused on the two principles of job creation and tax relief for middle-class families."
Obama has long favored stem cell research. In a 2007 news release, Obama said,"I am frustrated... that we are preventing the advancement of important science that could potentially impact millions of suffering Americans... My hope, and the hope of so many in this country, is to provide our researchers with the means to explore the uses of embryonic stem cells so that we can begin to turn the tide on the devastating diseases affecting our nation and our world."
- read more from Rahm Emanuel at the WSJ
- read the LA Times report for researchers' reactions
Related Articles:
Michigan voters supporting use of ESCs in research
Stem cell summit tackles thorny research issues
The 2008 Election: What does it mean for drugmakers?
Stem cell outfits a winner in upcoming election
Stem cell developers shift focus to FDA hearings
Comments
I am surprised that I haven't seen ANYTHING mentioned about Advanced Cell Technologies - the ONLY stem cell company which has SUCCESSFULLY retrieved stem cells from embryos without destroying it!!! This is the company that will advance the embryo stem cell field while dismissing the 'ethical' nature of same!!!
(ACTC) Advanced Cell Technology.....Will Rise To The Occasion!
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


